Profile data is unavailable for this security.
About the company
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
- Revenue in INR (TTM)8.11bn
- Net income in INR188.68m
- Incorporated1992
- Employees737.00
- LocationOrchid Pharma LtdOrchid Towers313-Valluvar Kottam High, NungambakkamGURGAON 122004IndiaIND
- Phone+91 4 425211000
- Fax+91 4 428211002
- Websitehttps://www.orchidpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | ORCHPHARMA:NSI since announced | Transaction value |
|---|---|---|
| Allecra Therapeutics SAS | -19.03% | -- |
Data delayed at least 15 minutes, as of Mar 04 2026 09:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 20.33bn | 1.78k | -- | -- | 25.79 | 1.62 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 22.27bn | 1.16bn | 20.95bn | 2.89k | 18.07 | -- | 10.77 | 0.9405 | 3.95 | 3.95 | 75.87 | -- | -- | -- | -- | 7,704,566.00 | -- | 10.26 | -- | 13.42 | 34.42 | 32.57 | 5.20 | 9.33 | -- | 10.46 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 22.63bn | 966.00 | 21.01 | -- | 15.37 | 2.61 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 22.86bn | 1.81k | 22.98 | -- | 15.50 | 1.28 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 23.21bn | 3.33k | 7.89 | -- | 5.54 | 1.05 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Hikal Ltd | 17.46bn | -130.00m | 23.69bn | 2.06k | -- | -- | 16.17 | 1.36 | -1.05 | -1.05 | 141.83 | -- | -- | -- | -- | 8,465,567.00 | -- | 4.78 | -- | 7.00 | 55.47 | 48.00 | -0.7447 | 5.71 | -- | 1.21 | -- | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 26.94bn | 1.11k | 22.68 | -- | 6.02 | 0.9631 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| Gufic BioSciences Ltd | 8.97bn | 500.38m | 27.93bn | 1.99k | 55.84 | -- | 34.46 | 3.11 | 4.99 | 4.99 | 89.42 | -- | -- | -- | -- | 4,513,114.00 | -- | 10.27 | -- | 16.11 | 55.87 | 46.41 | 5.58 | 10.48 | -- | 2.73 | -- | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 29.87bn | 1.33k | 14.74 | -- | 13.35 | 4.43 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Orchid Pharma Ltd | 8.11bn | 188.68m | 30.44bn | 737.00 | 161.39 | -- | 57.62 | 3.75 | 3.72 | 3.72 | 160.07 | -- | -- | -- | -- | 11,006,770.00 | -- | 1.40 | -- | 1.72 | 36.82 | 35.89 | 2.14 | 2.75 | -- | 0.4822 | -- | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 32.26bn | 221.00 | 67.51 | -- | 55.74 | 20.25 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 32.61bn | 1.28k | 16.19 | -- | 12.25 | 1.29 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 34.69bn | 1.47k | 36.58 | -- | 27.63 | 3.87 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| Senores Pharmaceuticals Ltd | 5.89bn | 1.02bn | 35.28bn | 194.00 | 34.18 | -- | 27.13 | 5.99 | 22.41 | 22.41 | 130.31 | -- | -- | -- | -- | 30,336,080.00 | -- | -- | -- | -- | 58.73 | -- | 17.48 | -- | -- | 5.94 | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| Innova Captab Ltd | 14.97bn | 1.32bn | 38.01bn | 1.95k | 28.72 | -- | 21.60 | 2.54 | 23.13 | 23.13 | 261.52 | -- | -- | -- | -- | 7,676,703.00 | -- | 10.02 | -- | 15.00 | 36.26 | 27.20 | 8.85 | 8.72 | -- | 12.45 | -- | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
Data as of Mar 04 2026. Currency figures normalised to Orchid Pharma Ltd's reporting currency: Indian Rupee INR
17.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Jan 2026 | 3.47m | 6.83% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 2.19m | 4.31% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Jan 2026 | 1.47m | 2.90% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 1.20m | 2.38% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 453.09k | 0.89% |
| Tata Asset Management Pvt Ltd.as of 31 Jan 2026 | 144.09k | 0.28% |
| ITI Asset Management Ltd. (India)as of 31 Jan 2026 | 70.76k | 0.14% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jan 2026 | 50.40k | 0.10% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 45.55k | 0.09% |
| WhiteOak Capital Asset Management Ltd.as of 31 Jan 2026 | 22.52k | 0.04% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
